| Title |
A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, May 2015
|
| DOI | 10.2147/ndt.s79347 |
| Pubmed ID | |
| Authors |
Ernie Anand, Lovisa Berggren, Claudia Deix, Ágoston Tóth, David P McDonnell |
| Abstract |
To assess the long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of schizophrenia, focusing on clinical trial data consistent with the approved indication and dosing recommendations in the European label and which forms the basis for treatment decisions made by clinicians in daily clinical practice. This was a post hoc analysis of a 6-year open-label study of olanzapine LAI in patients (male or female, 18-75 years old) with schizophrenia entering this study following feeder studies of olanzapine LAI. Patients were flexibly dosed (45-405 mg, 2- to 4-week intervals), but those receiving oral olanzapine supplementation whose total olanzapine dose was >20 mg/day equivalent were excluded from this post hoc analysis. Data from 669 patients were analyzed (44.5% completed). Positive and Negative Syndrome Scale total scores did not change significantly from baseline to endpoint; Clinical Global Impression-Severity scores improved significantly. Mean weight change was +2.19 kg (P<0.001), with 40.8% of patients experiencing ≥7% weight gain. There were 24 occurrences of post-injection delirium/sedation syndrome (PDSS). Olanzapine LAI appeared to be effective in the long-term maintenance of schizophrenia, and the safety profile was consistent with that of oral olanzapine, except for injection-related events and PDSS events. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 47 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 15% |
| Other | 6 | 13% |
| Student > Doctoral Student | 6 | 13% |
| Student > Master | 6 | 13% |
| Student > Ph. D. Student | 5 | 11% |
| Other | 10 | 21% |
| Unknown | 7 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 34% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 11% |
| Psychology | 5 | 11% |
| Nursing and Health Professions | 4 | 9% |
| Neuroscience | 3 | 6% |
| Other | 5 | 11% |
| Unknown | 9 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 June 2015.
All research outputs
#16,237,186
of 25,654,806 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,587
of 3,142 outputs
Outputs of similar age
#151,050
of 279,548 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#47
of 72 outputs
Altmetric has tracked 25,654,806 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,142 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.4. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,548 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 72 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.